At the news
? BEARISHIMPACT 7/10 8-K filed Apr 1, 2026 at 08:00 ET
Forte Biosciences reported a net loss per share of $(4.71) for FY 2025, missing consensus estimates, with R&D expenses nearly tripling due to clinical trial advancement. This follows a recent $150M follow-on offering, raising concerns about capital efficiency.
- Net loss per share was $(4.71) for FY 2025, missing consensus of $-1.16
- R&D expenses increased to $58.2M from $21.2M in 2024 due to clinical trials
- Cash and cash equivalents decreased to $77.0M from $93.4M in Q3 2025
- Recent $150M follow-on offering completed just 12 days prior to earnings
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access